Solasia Pharma K.K.
Start of Sales of Epicele in Brazil and Future Revenue Outlook｜July 2026
The start of sales of Epicele in Brazil has been completed, with sales scheduled to begin in Q4 2026. Revenue is reflected in the FY2026 financial statements, and milestone income is also anticipated.
Key Figures
- Completion of registration for the start of sales of Epicele in Brazil
- Revenue forecast for Epicele sales in FY2026 has already been announced
- Milestone income is scheduled to be recognized in the third quarter of this fiscal year
AI要約
Performance Overview
This document reports the completion of registration for the start of sales of Epicele in Brazil and the plan to begin sales from Q4 2026. Sales are expected to be reflected in the consolidated results for FY2026, and milestone income is also scheduled to be received. The sales revenue forecast has already been announced.
Future Outlook and Impact on Revenue
The initiation of sales in Brazil is expected to advance the monetization of Epicele. In FY2026, sales revenue will be recorded, and milestone income will be earned, contributing to expected revenue growth. However, specific sales figures and revenue amounts have not been disclosed.
Sorejiah Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
